KPI-121 1% for Pain and Inflammation in Ocular Surgery

Abstract

Pain and inflammation are common experiences following ocular surgery and, if uncontrolled, can compromise patients’ vision, functioning and quality of life. Corticosteroid drugs are available to manage inflammation and discomfort but have limitations in penetrating the ocular mucus barrier to reach the target ocular tissues. KPI-121 1% (INVELTYS^®) is a novel formulation of loteprednol etabonate that employs innovative proprietary technology to deliver nanoparticle-sized mucus-penetrating particles to the cornea. Results from clinical trials demonstrate that KPI-121 1% is effective and well tolerated. KPI-121 1% uses mucopenetrative technology for ophthalmic use and is the only US FDA-approved twice-daily ocular corticosteroid indicated for the treatment of inflammation and pain after ocular surgery.

Tweetable abstract

KPI-121 1% (#INVELTYS), a well-tolerated/effective formulation of #loteprednol #etabonate, uses novel mucus-penetrating nanoparticle technology. It is the only US FDA-approved twice-daily ocular corticosteroid for the treatment of inflammation and pain after ocular surgery.

Keywords::

• corticosteroid
• INVELTYS^®
• KPI-121 1%
• loteprednol etabonate
• mucus-penetrating particles and/or nanoparticles
• ocular pain
• ocular surgery
• postoperative ocular inflammation

Financial & competing interest disclosure

KA Beckman has received consultancy fees from Alcon, Allergan, Bausch + Lomb, a division of Bausch Health US, LLC, Eyevance Pharmaceuticals, Kala Pharmaceuticals, Novartis and Sun Pharmaceutical Industries Ltd. AT Rostov has received consultancy fees from Alcon, Allergan, Bausch + Lomb, a division of Bausch Health US, LLC, Kala Pharmaceuticals, Novartis and Sun Pharmaceutical Industries Ltd. PA Majmudar has received consultancy fees from Alcon, Allergan, Bausch + Lomb, a division of Bausch Health US, LLC, Bio-Tissue, Inc., Dompé, Eyevance Pharmaceuticals, Kala Pharmaceuticals, Novaliq, Novartis and Sun Pharmaceutical Industries Ltd. JA Katz has received consultancy fees from Allergan, EyePoint Pharmaceuticals, Inc., Eyevance Pharmaceuticals, Kala Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Novartis, Ocular Science and Ocular Therapeutix. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Editorial support was provided by EA Kuhl, L Baker, and E Tazartes of the Global Outcomes Group and was funded by Kala Pharmaceuticals.

Additional information

Funding

KA Beckman has received consultancy fees from Alcon, Allergan, Bausch + Lomb, a division of Bausch Health US, LLC, Eyevance Pharmaceuticals, Kala Pharmaceuticals, Novartis and Sun Pharmaceutical Industries Ltd. AT Rostov has received consultancy fees from Alcon, Allergan, Bausch + Lomb, a division of Bausch Health US, LLC, Kala Pharmaceuticals, Novartis and Sun Pharmaceutical Industries Ltd. PA Majmudar has received consultancy fees from Alcon, Allergan, Bausch + Lomb, a division of Bausch Health US, LLC, Bio-Tissue, Inc., Dompé, Eyevance Pharmaceuticals, Kala Pharmaceuticals, Novaliq, Novartis and Sun Pharmaceutical Industries Ltd. JA Katz has received consultancy fees from Allergan, EyePoint Pharmaceuticals, Inc., Eyevance Pharmaceuticals, Kala Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Novartis, Ocular Science and Ocular Therapeutix. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Editorial support was provided by EA Kuhl, L Baker, and E Tazartes of the Global Outcomes Group and was funded by Kala Pharmaceuticals.